Risk of Adverse Cardiovascular Outcomes in Postmenopausal Women with Inflammatory Bowel Disease.
Cardiovascular disease
Inflammatory bowel disease
Postmenopausal
Stroke
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
28
06
2023
accepted:
08
02
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
Individuals with inflammatory bowel disease (IBD) who lack traditional cardiovascular disease (CVD) risk factors, such as young females, are observed to experience adverse CVD outcomes. Whether women with IBD have increased CVD risk after the menopause transition is unclear. We conducted a survival analysis of Women's Health Initiative (WHI) participants and excluded those with missing IBD diagnosis, model covariate data, follow-up data, or a baseline history of the following CVD outcomes: coronary heart disease (CHD), ischemic stroke, venous thromboembolism (VTE), peripheral arterial disease (PAD). Risk of outcomes between IBD and non-IBD women was performed using Cox proportional hazard models, stratified by WHI trial and follow-up. Models were adjusted for age, socio-demographics, comorbidities (e.g., hypertension, diabetes, hypercholesterolemia, etc.), family history, and lifestyle factors (e.g., smoking, alcohol, physical activity, body mass index, etc.). Of 134,022 WHI participants meeting inclusion criteria, 1367 (1.0%) reported IBD at baseline. Mean baseline age was 63.4 years. After adjusting for age and other confounders, no significant difference was observed between IBD and non-IBD women for the risk of CHD (HR 0.96, 95% CI 0.73-1.24), VTE (HR 1.11, 95% CI 0.81-1.52) or PAD (HR 0.64, 95% CI 0.28-1.42). After adjusting for age, risk of ischemic stroke was significantly higher (HR 1.41, 95% CI 1.06-1.88) in IBD than non-IBD women. With further adjustment, the excess risk of ischemic stroke among IBD women was attenuated and no longer statistically significant (HR 1.31, 95% CI 0.98-1.76). Among postmenopausal women with IBD, risk of ischemic stroke may be higher than in non-IBD women.
Sections du résumé
BACKGROUND
BACKGROUND
Individuals with inflammatory bowel disease (IBD) who lack traditional cardiovascular disease (CVD) risk factors, such as young females, are observed to experience adverse CVD outcomes. Whether women with IBD have increased CVD risk after the menopause transition is unclear.
METHODS
METHODS
We conducted a survival analysis of Women's Health Initiative (WHI) participants and excluded those with missing IBD diagnosis, model covariate data, follow-up data, or a baseline history of the following CVD outcomes: coronary heart disease (CHD), ischemic stroke, venous thromboembolism (VTE), peripheral arterial disease (PAD). Risk of outcomes between IBD and non-IBD women was performed using Cox proportional hazard models, stratified by WHI trial and follow-up. Models were adjusted for age, socio-demographics, comorbidities (e.g., hypertension, diabetes, hypercholesterolemia, etc.), family history, and lifestyle factors (e.g., smoking, alcohol, physical activity, body mass index, etc.).
RESULTS
RESULTS
Of 134,022 WHI participants meeting inclusion criteria, 1367 (1.0%) reported IBD at baseline. Mean baseline age was 63.4 years. After adjusting for age and other confounders, no significant difference was observed between IBD and non-IBD women for the risk of CHD (HR 0.96, 95% CI 0.73-1.24), VTE (HR 1.11, 95% CI 0.81-1.52) or PAD (HR 0.64, 95% CI 0.28-1.42). After adjusting for age, risk of ischemic stroke was significantly higher (HR 1.41, 95% CI 1.06-1.88) in IBD than non-IBD women. With further adjustment, the excess risk of ischemic stroke among IBD women was attenuated and no longer statistically significant (HR 1.31, 95% CI 0.98-1.76).
CONCLUSIONS
CONCLUSIONS
Among postmenopausal women with IBD, risk of ischemic stroke may be higher than in non-IBD women.
Identifiants
pubmed: 38684633
doi: 10.1007/s10620-024-08348-2
pii: 10.1007/s10620-024-08348-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1TR001073
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:41–45.
doi: 10.1016/j.cgh.2007.09.016
pubmed: 18063423
Osterman MT, Yang YX, Brensinger C, Forde KA, Lichtenstein GR, Lewis JD. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn’s disease. Clin Gastroenterol Hepatol 2011;9:875–880.
doi: 10.1016/j.cgh.2011.06.032
pubmed: 21749853
pmcid: 3183342
Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013;62:689–694.
doi: 10.1136/gutjnl-2012-303285
pubmed: 22961677
Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014;8:469–479.
doi: 10.1016/j.crohns.2013.09.021
pubmed: 24183231
Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382–93 e1: quiz e22.
Barnes EL, Beery RM, Schulman AR, McCarthy EP, Korzenik R, Winter RW. Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. Inflamm Bowel Dis 2016;22:2229–2237.
doi: 10.1097/MIB.0000000000000899
pubmed: 27542135
Aniwan S, Pardi DS, Tremaine WJ, Tremaine WJ, Loftus EV. Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2018;16:1607-1615.e1.
doi: 10.1016/j.cgh.2018.04.031
pubmed: 29702298
pmcid: 6152828
Card TR, Zittan E, Nguyen GC, Grainge MJ. Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease. Inflamm Bowel Dis 2021;27:629–638.
doi: 10.1093/ibd/izaa156
pubmed: 32618340
Bernstein CN, Nugent Z, Singh H. Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study. Am J Gastroenterol 2021;116:1476–1484.
doi: 10.14309/ajg.0000000000001237
pubmed: 33767104
Panhwar MS, Mansoor E, Al-Kindi SG, Sinh P et al. Risk of Myocardial Infarction in Inflammatory Bowel Disease: A Population-based National Study. Inflamm Bowel Dis 2019;25:1080–1087.
doi: 10.1093/ibd/izy354
pubmed: 30500938
Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 2015;12:26–35.
doi: 10.1038/nrgastro.2014.202
pubmed: 25446727
Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471–478.
doi: 10.1002/ibd.21417
pubmed: 20725943
Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death–a Danish nationwide cohort study. PLoS One 2013;8:e56944.
doi: 10.1371/journal.pone.0056944
pubmed: 23457642
pmcid: 3574079
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657–663.
doi: 10.1016/S0140-6736(09)61963-2
pubmed: 20149425
Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009;104:1445–1451.
doi: 10.1038/ajg.2009.81
pubmed: 19491858
Roifman I, Sun YC, Fedwick JP, Panaccione R et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009;7:175–182.
doi: 10.1016/j.cgh.2008.10.021
pubmed: 19121648
Wu GC, Leng RX, Lu Q, Fan YG, Wang DG, Ye DQ. Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Angiology 2017;68:447–461.
doi: 10.1177/0003319716652031
pubmed: 27252243
Nevulis MG, Baker C, Lebovics E, Frishman WH. Overview of Link Between Inflammatory Bowel Disease and Cardiovascular Disease. Cardiol Rev 2018;26:287–293.
doi: 10.1097/CRD.0000000000000214
pubmed: 30277903
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–1143.
doi: 10.1161/hc0902.104353
pubmed: 11877368
Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363–368.
doi: 10.1161/01.CIR.0000153339.27064.14
pubmed: 15668353
Frostegard J. Systemic lupus erythematosus and cardiovascular disease. Lupus 2008;17:364–367.
doi: 10.1177/0961203308089988
pubmed: 18490408
Manzi S, Meilahn E, Rairie J, Conte C et al. Age-specific incidence MI angina women SLE Framingham comparison. American Journal of Epidemiology 1997;145:408–415.
doi: 10.1093/oxfordjournals.aje.a009122
pubmed: 9048514
Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015;11:693–704.
doi: 10.1038/nrrheum.2015.112
pubmed: 26282082
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524–1529.
doi: 10.1136/annrheumdis-2011-200726
pubmed: 22425941
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132–140.
doi: 10.1016/S0140-6736(09)61717-7
pubmed: 20031199
Bigeh A, Sanchez A, Maestas C, Gulati M. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? Trends Cardiovasc Med 2020;30:463–469.
doi: 10.1016/j.tcm.2019.10.001
pubmed: 31653485
Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21–29.
doi: 10.7326/0003-4819-145-1-200607040-00128
pubmed: 16818925
El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation 2020;142:e506–e532.
doi: 10.1161/CIR.0000000000000912
pubmed: 33251828
El Khoudary SR, Wildman RP, Matthews K, Thurston RC et al. Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. Atherosclerosis 2012;225:180–186.
doi: 10.1016/j.atherosclerosis.2012.07.025
pubmed: 22981430
pmcid: 3478422
Matthews KA, Crawford SL, Chae CU, Everson-Rose SA et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009;54:2366–2373.
doi: 10.1016/j.jacc.2009.10.009
pubmed: 20082925
pmcid: 2856606
Gurka MJ, Vishnu A, Santen RJ, DeBoer MD. Progression of Metabolic Syndrome Severity During the Menopausal Transition. J Am Heart Assoc 2016;5.
Maas A, Rosano G, Cifkova R, Chieffo A et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967–984.
doi: 10.1093/eurheartj/ehaa1044
pubmed: 33495787
pmcid: 7947184
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61–109.
Curb JD, McTiernan A, Heckbert SR, Koperberg C et al. Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 2003;13:S122–S128.
doi: 10.1016/S1047-2797(03)00048-6
pubmed: 14575944
Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 2012;120:595–603.
doi: 10.1097/AOG.0b013e318265df42
pubmed: 22914469
pmcid: 3607288
Ridker PM, Cook NR, Lee IM, Gordon D et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
doi: 10.1056/NEJMoa050613
pubmed: 15753114
Abdelaziz HK, Saad M, Pothineni NVK, Megaly M et al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol 2019;73:2915–2929.
doi: 10.1016/j.jacc.2019.03.501
pubmed: 31196447
Davidson KW, Barry MJ, Mangione M, Cabana CM et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA 2022;327:1577–1584.
doi: 10.1001/jama.2022.5207
pubmed: 35471505
Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol 2015;50:255–263.
doi: 10.3109/00365521.2014.966753
pubmed: 25314574
Patel P, Gao G, Gulotta G, Dalal S et al. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:236–241.
doi: 10.1093/ibd/izaa060
pubmed: 32219391
Takeuchi K, Smale S, Premchand P, Maiden L, et al. Prevalence and mechanism of NSAID clinical relapse in IBD. Clin Gastroenterol Hepatol 2006:196–202.